Abstract
Behçet syndrome (BS) starts early and may last a long time so that the whole of the working life and the family can be compromised by the disease process. A few disease assessment measures have been studied in BS. The ones that have been developed specifically for BS are small in number, and most lack coverage for some manifestations of the disease, which may be seen with different frequencies in different parts of the world, such as gastrointestinal and neurological involvement. Eye involvement, the main cause of morbidity, still lacks good and easy to use assessment tools, while new tools are available for the assessment of skin and mucosa involvement. Efforts are ongoing for developing a validated Core Set of Outcome Measures for BS.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Sut N, Seyahi E, Yurdakul S, Senocak M, Yazici H. A cost analysis of Behçet’s syndrome in Turkey. Rheumatology (Oxford). 2007;46:678–82.
Watt RG. Strategies and approaches in oral disease prevention and health promotion. Bull World Health Organ. 2005;83:711–8.
Nelson EC, Eftimovska E, Lind C, Hager A, Wasson JH, Lindblad S. Patient reported outcome measures in practice. BMJ. 2015;350:g7818.
Deshpande PR, Rajan S, Sudeepthi BL, Abdul Nazir CP. Patient-reported outcomes: a new era in clinical research. Perspect Clin Res. 2011;2(4):137–44.
Ni Riordain R, Shirlaw P, Alajbeg I, Al Zamel GY, Fung PL, Yuan AD, et al. World Workshop on Oral Medicine VI: patient-reported outcome measures and oral mucosal disease: current status and future direction. Oral Surg Oral Med Oral Pathol Oral Radiol. 2015;120(2):152–60. e111
Mumcu G, Alibaz-Oner F, Oner SY, Ozen G, Atagunduz P, Inanc N, et al. Oral ulcer activity in Behcet’s disease: poor medication adherence is an underestimated risk factor. Eur J Rheumatol. 2017;4(2):109–12.
Hatemi G, Merkel PA, Hamuryudan V, Boers M, Direskeneli H, Aydin SZ, et al. Outcome measures used in clinical trials for Behçet syndrome: a systematic review. J Rheumatol. 2014;41:599–612.
Prevoo ML, Van’t Hof MA, Kuper HH, van Leeuwen MA, van de Putte LB, van Riel PL. Modified disease activity scores that include twenty-eight-joint counts. Development and validation in a prospective longitudinal study of patients with rheumatoid arthritis. Arthritis Rheum. 1995;38:44–8.
Yazici H, Tuzun Y, Pazarli H, Yurdakul S, Ozyazgan Y, Ozdogan H, et al. Influence of age of onset and patient’s sex on the prevalence and severity of manifestations of Behçet’s syndrome. Ann Rheum Dis. 1984;43:783–9.
Lawton G, Bhakta BB, Chamberlain MA, Tennant A. The Behçet’s disease activity index. Rheumatology (Oxford). 2004;43:73–8.
Beaton DE. Understanding the relevance of measured change through studies of responsiveness. Spine. 2000;25:3192–9.
Lee ES, Kim HS, Bang D, Yu HG, Chung H, Shin DH, et al. Development of clinical activity form for Korean patients with Behçet’s disease. Adv Exp Med Biol. 2003;528:153–6.
Neves FS, Moraes JC, Kowalski SC, Goldenstein-Schainberg C, Lage LV, Gonçalves CR. Cross-cultural adaptation of the Behçet’s Disease Current Activity Form (BDCAF) to Brazilian Portuguese language. Clin Rheumatol. 2007;26:1263–7.
Hamuryudan V, Fresko I, Direskeneli H, Tenant MJ, Yurdakul S, Akoglu T, Yazici H. Evaluation of the Turkish translation of a disease activity form for Behçet’s syndrome. Rheumatology (Oxford). 1999;38:734–6.
Forbess C, Swearingen C, Yazici Y. Behçet’s Syndrome Activity Score (BSAS): a new disease activity assessment tool, composed of patient-derived measures only, is strongly correlated with The Behçet’s Disease Current Activity Form (BDCAF). Ann Rheum Dis. 2008;67(SII):360.
Shahram F, Khabbazi A, Nadji A, Ziaie N, Banihashemi AT, Davatchi F. Comparison of existing disease activity indices in the follow-up of patients with Behçet’s disease. Mod Rheumatol. 2009;19(5):536–41.
Simsek I, Meric C, Erdem H, Pay S, Kilic S, Dinc A. Accuracy of recall of the items included in disease activity forms of Behçet’s disease: comparison of retrospective questionnaires with a daily telephone interview. Clin Rheumatol. 2008;27:1255–60.
Bang D, Kim HS, Lee ES, Lee S. The significance of laboratory test in evaluating the clinical activity of Behçet’s disease. In: Proceedings of the 9th international conference in Behçet’s disease held in Seoul, Korea, 27–29 May; 2000.
Deuter CME, Kotter I, Gunaydin I, Zierhut M, Stubiger N. Ocular involvement in Behçet’s disease: first 5-year-results for visual development after treatment with interferon alfa-2a. Ophthalmologe. 2004;101:129–34.
Amberger M, Groll S, Günaydin I, Deuter C, Vonthein R, Kötter I. Intracellular cytokine patterns in Behçet’s disease in comparison to ankylosing spondylitis – influence of treatment with interferon-alpha2a. Clin Exp Rheumatol. 2007;25(Suppl 45):S52–7.
Kötter I, Koch S, Vonthein R, Rückwaldt U, Amberger M, Günaydin I, et al. Cytokines, cytokine antagonists and soluble adhesion molecules in patients with ocular Behçet’s disease treated with human recombinant interferon-alpha2a. Results of an open study and review of the literature. Clin Exp Rheumatol. 2005;23(Suppl 38):S20–6.
Cekmen M, Evereklioglu C, Er H, Inaloz HS, Doganay S, Yurkoz Y, Ozerol IH. Vascular endothelial growth factor levels are increased and associated with disease activity in patients with Behçet’s syndrome. Int J Dermatol. 2003;42(11):870–5.
Nanke Y, Kotake S, Goto M, Ujihara H, Matsubara M, Kamatani N. Decreased percentages of regulatory T cells in peripheral blood of patients with Behçet’s disease before ocular attack: a possible predictive marker of ocular attack. Mod Rheumatol. 2008;18(4):354–8.
Pay S, Abbasov T, Erdem H, Musabak U, Simsek I, Pekel A, et al. Serum MMP-2 and MMP-9 in patients with Behçet’s disease: do their higher levels correlate to vasculo-Behçet’s disease associated with aneurysm formation? Clin Exp Rheumatol. 2007;25(Suppl 45):S-70–5.
Kim DH, Park Y, Kim B, Kim SW, Park SJ, Hong SP, et al. Fecal calprotectin as a non-invasive biomarker for intestinal involvement of Behçet’s disease. J Gastroenterol Hepatol. 2017;32(3):595–601.
Esatoglu SN, Hatemi I, Ozguler Y, Hatemi G, Uzun H, Celik AF, Yazici H. Faecal but not serum calprotectin levels look promising in predicting active disease in Behçet’s syndrome patients with gastrointestinal involvement. Clin Exp Rheumatol. 2018;36(6 Suppl 115):90–6.
Tugal-Tutkun I, Herbort CP, Khairallah M. The Angiography Scoring for Uveitis Working Group (ASUWOG). Scoring of dual fluorescein and ICG inflammatory angiographic signs for the grading of posterior segment inflammation (dual fluorescein and ICG angiographic scoring system for uveitis). Int Ophthalmol. 2010;30(5):539–52.
Kaburaki T, Namba K, Sonoda KH, Kezuka T, Keino H, Fukuhara T, et al. Behçet’s disease ocular attack score 24: evaluation of ocular disease activity before and after initiation of infliximab. Jpn J Ophthalmol. 2014;58(2):120–30.
Tugal-Tutkun I, Cingu K, Kir N, et al. Use of laser flare-cell photometry to quantify intraocular inflammation in patients with Behçet’s uveitis. Graefes Arch Clin Exp Ophthalmol. 2008;246:1169–77.
Yalcindag FN, Bingol Kiziltunc P, Savku E. Evaluation of intraocular inflammation with laser flare photometry in Behçet uveitis. Ocul Immunol Inflamm. 2017;25:41–5.
Mesquida M, Llorenç V, Fontenla JR, et al. Use of ultrawide-field retinal imaging in the management of active Behçet retinal vasculitis. Retina. 2014;34:2121–7.
Moon SW, Kim BH, Park UC, Yu HG. Inter-observer variability in scoring ultra-wide-field fluorescein angiography in patients with Behçet retinal vasculitis. Ocul Immunol Inflamm. 2017;25(1):20–8.
Nussenblatt RB, Pelestine AG, Chan CC, et al. Standardization of vitreal inflammatory activity in intermediate and posterior uveitis. Ophthalmology. 1985;92:467–71.
Davis JL, Madow B, Cornett J, et al. Scale for photographic grading of vitreous haze in uveitis. Am J Ophthalmol. 2010;150:637–41.
Ozyazgan Y, Ucar D, Erdogan M, Ozguler Y, Hatemi G, Yurdakul S, et al. Factors associated with damage progression in Behçet’s syndrome uveitis. Arthritis Rheumatol. 2018;70(suppl 10)
Mumcu G, Inanc N, Taze A, Ergun T, Direskeneli H. A new mucocutaneous activity index for Behcet’s disease. Clin Exp Rheumatol. 2014;32(4 Suppl 84):S8–6.
Mumcu G, Sur H, Inanc N, Karacayli U, Cimilli H, Sisman N, et al. A composite index for determining the impact of oral ulcer activity in Behcet’s disease and recurrent aphthous stomatitis. J Oral Pathol Med. 2009;38(10):785–91.
Senusi A, Higgins S, Fortune F. The influence of oral health and psycho-social well-being on clinical outcomes in Behcet’s disease. Rheumatol Int. 2018;38(10):1873–83.
Mumcu G, Inanc N, Ergun T, Ikiz K, Gunes M, Islek U, et al. Oral health related quality of life ıs affected by disease activity ın Behçet’s disease. Oral Dis. 2006;12:145–51.
Mumcu G, Niazi S, Stewart J, Hagi-Pavli E, Gokani B, Seoudi N, et al. Oral health and related quality of life status in patients from UK and Turkey: a comparative study in Behçet’s disease. J Oral Pathol Med. 2009;38:406–9.
Sogur E, Onem E, Kalfa M, Emmungil H, Bostanci N, Aksu K, et al. Oral health and oral quality of life in inactive patients with familial Mediterranean fever without amyloidosis. Clin Exp Rheumatol. 2013;31(3 Suppl 77):15–9.
Mumcu G, Hayran O, Ozalp DO, Inanc N, Yavuz S, Ergun T, Direskeneli H. The assessment of oral health related quality of life by factor analysis in patients with Behçet’s disease and recurrent apthous stomatitis. J Oral Pathol Med. 2007;36:147–52.
Hayran O, Mumcu G, Inanc N, Ergun T, Direskeneli H. Assessment of minimal clinically important improvement by using Oral Health Impact Profile-14 in Behcet’s disease. Clin Exp Rheumatol. 2009;27(2 Suppl 53):S79–84.
Mumcu G. Behcet’s disease: a dentist’s overview. Clin Exp Rheumatol. 2008;26(4 Suppl 50):S121–4.
Alibaz-Oner F, Mumcu G, Kubilay Z, Ozen G, Celik G, Karadeniz A, Can M, Oner SY, Inanc N, Atagunduz P, Ergun T, Direskeneli H. Unmet need in Behcet’s disease: most patients in routine follow-up continue to have oral ulcers. Clin Rheumatol. 2014;33(12):1773–6.
Coit P, Mumcu G, Ture-Ozdemir F, Unal AU, Alpar U, Bostanci N, et al. Sequencing of 16S rRNA reveals a distinct salivary microbiome signature in Behcet’s disease. Clin Immunol. 2016;169:28–35.
Mumcu G, Cimilli H, Karacayli U, Inanc N, Ture-Ozdemir F, Eksioglu-Demiralp E, et al. Salivary levels of HNP 1-3 are related to oral ulcer activity in Behcet’s disease. Int J Dermatol. 2013;52(10):1198–201.
Karacayli U, Mumcu G, Simsek I, Pay S, Kose O, Erdem H, et al. The close association between dental and periodontal treatments and oral ulcer course in behcet’s disease: a prospective clinical study. J Oral Pathol Med. 2009;38(5):410–5.
Senusi A, Seoudi N, Bergmeier LA, Fortune F. Genital ulcer severity score and genital health quality of life in Behcet’s disease. Orphanet J Rare Dis. 2015;10:117.
Seyahi E, Cakmak OS, Tutar B, Arslan C, Dikici AS, Sut N, et al. Clinical and ultrasonographic evaluation of lower-extremity vein thrombosis in Behcet syndrome: an observational study. Medicine (Baltimore). 2015;94(44):e1899.
Alibaz-Oner F, Aldag B, Aldag M, Unal AU, Mutiş A, Toptas T, et al. Post-thrombotic syndrome and venous disease-specific quality of life in patients with vascular Behçet’s disease. J Vasc Surg Venous Lymphat Disord. 2016;4(3):301–6.
Mioshi E, Dawson K, Mitchell J, Arnold R, Hodges JR. The Addenbrooke’s Cognitive Examination Revised (ACE-R): a brief cognitive test battery for dementia screening. Int J Geriatr Psychiatry. 2006;21:1078–85.
Siva A, Kantarci OH, Saip S, Altintas A, Hamuryudan V, Islak C, et al. Behçet’s disease: diagnostic and prognostic aspects of neurologic involvement. J Neurol. 2001;248:95–103.
Cheon JH, Han DS, Park JY, Ye BD, Jung SA, Park YS, et al. Development, validation, and responsiveness of a novel disease activity index for intestinal Behcet’s disease. Inflamm Bowel Dis. 2011;17:605–13.
Best WR, Becktel JM, Singleton JW, Kern FJ. Development of a Crohn’s disease activity index. National Cooperative Crohn’s Disease Study. Gastroenterology. 1976;70(3):439–44.
Moses Alder N, Fisher M, Yazici Y. Behçet’s syndrome patients have high levels of functional disability, fatigue and pain as measured by a Multi-dimensional Health Assessment Questionnaire (MDHAQ). Clin Exp Rheumatol. 2008;26(Suppl 50):S110–3.
Mumcu G, Lehimci F, Fidan O, Guk H, Alpar U, Unal AU, et al. The assessment of work productivity and activity impairment in Behcet’s disease. Turk J Med Sci. 2017;47(2):535–41.
Serin N, Ozguler Y, Esatoglu SN, Hamuryudan V, Hatemi G. Work productivity is impaired in patients with Behçet’s syndrome. Arthritis Rheumatol. 2018;70(suppl 10).
Yankouskaya A, Boughey A, McCagh J, Neal A, de Bezenac C, Davies SJ. Illness perception mediates the relationship between the severity of symptoms and perceived health status in patients with Behcet disease. J Clin Rheumatol. 2018; https://doi.org/10.1097/RHU.0000000000000872.
Grayson PC, Amudala NA, McAlear CA, Leduc RL, Shereff D, Richesson R, et al. Causal attributions about disease onset and relapse in patients with systemic vasculitis. J Rheumatol. 2014;41(5):923–30.
Mumcu G, Yağar F, Alibaz-Öner F, İnanç N, Direskeneli H, Ergun T. Does illness perception associate with disease symptoms in Behçet’s disease? Intern Emerg Med. 2018; https://doi.org/10.1007/s11739-018-1983-y.
Bodur H, Borman P, Ozdemir Y, Atan C, Kural G. Quality of life and life satisfaction in patients with Behçet’s disease: relationship with disease activity. Clin Rheumatol. 2006;25:329–33.
Gilworth G, Chamberlain MA, Bhakta B, Haskard D, Silman A, Tennant A. Development of the Behçet’s disease quality of life, a quality of life measure specific to Behçet’s disease. J Rheumatol. 2004;31:931–7.
Hatemi G, Ozguler Y, Direskeneli H, Mahr A, Gul A, Levi V, et al. Current status, goals, and research agenda for outcome measures development in Behçet syndrome: report from OMERACT 2014. J Rheumatol. 2015;42(12):2436–41.
Hatemi G, Meara A, Ozguler Y, Direskeneli H, Mahr A, Easley E, et al. Developing a core set of outcome measures for Behçet disease: report from OMERACT 2016. J Rheumatol. 2017;44:1750–3.
Ozguler Y, Merkel PA, Gurcan M, Bocage C, Eriksen W, Hatemi G, et al. Patients’experiences with Behçet’s syndrome: Structured interviews among patients with different types of organ involvement. Clin Exp Rheum. 2019; (in press).
Hatemi G, Meara A, Ozguler Y, Direskeneli H, Mahr A, Shea B, et al. The OMERACT Core Domain Set for clinical trials in Behçet’s syndrome. Arthritis Rheumatol. 2018;70 (suppl 10).
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2020 Springer Nature Switzerland AG
About this chapter
Cite this chapter
Mumcu, G., Yazici, Y., Hatemi, G. (2020). Disease Assessment in Behçet Syndrome. In: Yazici, Y., Hatemi, G., Seyahi, E., Yazici, H. (eds) Behçet Syndrome. Springer, Cham. https://doi.org/10.1007/978-3-030-24131-5_19
Download citation
DOI: https://doi.org/10.1007/978-3-030-24131-5_19
Published:
Publisher Name: Springer, Cham
Print ISBN: 978-3-030-24130-8
Online ISBN: 978-3-030-24131-5
eBook Packages: MedicineMedicine (R0)